Physician profile
Robert Platzman
NPI 1497852966
$1,936.00
in general payments reported to CMS, 2019-2025
37 companies · $775 in 2025
The $775 reported for 2025 was more than what 86% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $105 · 2021: $117 · 2024: $369 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $146.87 | 2024 | |
| Acadia Pharmaceuticals INC | $138.71 | 2019-2025 | Nuplazid |
| Pfizer INC. | $112.37 | 2019-2025 | |
| Amgen INC. | $111.44 | 2024-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $102.56 | 2021-2025 | Airsupra, Lokelma, Breztri |
| Lundbeck LLC | $98.89 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $94.70 | 2019 | |
| Alpha Cognition USA, INC. | $93.30 | 2025 | Zunveyl |
| Novartis Pharmaceuticals Corporation | $92.27 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.59 | 2021-2025 | Caplyta |
| Exact Sciences Corporation | $90.27 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $88.12 | 2025 | |
| Abbvie INC. | $72.37 | 2019-2020 | |
| Lilly USA, LLC | $64.83 | 2024-2025 | Zepbound, Mounjaro |
| Eisai INC. | $63.00 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $50.18 | 2019-2025 | Rexulti |
| Amarin Pharma, INC. | $43.19 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.06 | 2019-2020 | |
| Boston Scientific Corporation | $31.47 | 2025 | General - Dbs |
| Merck Sharp & Dohme LLC | $28.12 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.29 | 2019 | |
| C2n Diagnostics, LLC | $24.24 | 2025 | Precivityad2 |
| Insightec,INC | $22.58 | 2025 | Exablate |
| Sunovion Pharmaceuticals INC. | $22.45 | 2020 | |
| Acorda Therapeutics, INC | $15.00 | 2019 | |
| Sanofi Pasteur INC. | $15.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.00 | 2025 | Nuzyra |
| Astellas Pharma US INC | $14.83 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.36 | 2019 | |
| Ucb, INC. | $14.16 | 2019 | |
| Biogen, INC. | $13.87 | 2021 | |
| Glaxosmithkline, LLC. | $12.26 | 2021 | |
| Kyowa Kirin, INC. | $12.14 | 2020 | |
| Allergan, INC. | $11.81 | 2019 | |
| Novo Nordisk INC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Platzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.